Should Phase III Colon Cancer Trial Require Action From Akeso (SEHK:9926) Investors?

• Akeso reported that the first patient has been dosed in a Phase III trial of cadonilimab as perioperative monotherapy for resectable MSI-H/dMMR colon cancer, expanding the antibody's evaluation beyond gastric, lung, and cervical indications.
• The move into perioperative colon cancer targets an area where conventional chemotherapy delivers around 7% pathological response rates. If outcomes are positive, this could influence how Akeso allocates R&D and commercial resources around cadonilimab.
• Investors and other stakeholders will be watching how Akeso's investment narrative might be affected by cadonilimab's Phase III move into perioperative colon cancer.

Capture where immuno-oncology momentum is building by scanning 126 healthcare AI stocks, aligned with breakthroughs like Akeso's push into perioperative MSI-H/dMMR colon cancer.

Akeso Investment Narrative Recap

To own Akeso, you need to believe its bispecific antibody platform can turn a broad late stage pipeline into meaningful commercial scale, despite current losses. The perioperative MSI H/dMMR colon cancer trial adds to that bet but does not change the near term story, which centers on execution in existing indications and tighter cost discipline.

The most important short term catalyst still lies in how quickly cadonilimab and ivonescimab convert into wider real world use, especially in relation to National Reimbursement Drug List coverage and hospital reach. The largest risk remains heavy dependence on a few drugs while running sizeable operating and EBITDA losses that pressure cash needs.

The new Phase III perioperative colon cancer study links directly to one of Akeso's key operational themes. Management is relying on multiple late stage trials for cadonilimab and ivonescimab across tumor types to build a wider IO 2.0 footprint. This colon cancer initiative increases that footprint and concentrates more value in cadonilimab outcomes.

Previous communication about aiming for National Reimbursement Drug List inclusion for both bispecifics by 2025 is still the key operational swing factor to watch. Positive reimbursement decisions together with continued trial progress would support the revenue side of the story. Delays, weaker uptake, or trial setbacks would magnify existing profitability and concentration risks.

Akeso's current analyst narrative points to CN¥12.0b in revenue and CN¥3.2b in earnings by 2029. That profile relies on a forecast 51.4% yearly revenue growth rate and an earnings swing of roughly CN¥4.2b, from a loss of CN¥967.2m today to the projected CN¥3.2b profit.

Uncover how Akeso's fair value indicates a 44% potential upside to its current price before that gap closes.

Exploring Other Perspectives

You see a very different story if you focus on the bullish catalyst of faster product uptake. The most optimistic analysts were already pencilling in CN¥14.4b of revenue and CN¥5.3b of earnings by 2029, before this perioperative colon cancer trial started. This development could push those views even further. That gap to the consensus forecast shows how widely opinions differ, so it helps to compare several narratives before deciding how Akeso fits your own risk and return expectations.

Explore 3 other Akeso fair value estimates, including one that suggests as much as 61% upside from the current price.

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Akeso research is our analysis highlighting 2 key rewards that could impact your investment decision.
• See our latest analysis for Akeso. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Akeso's overall financial health at a glance.

Looking For More Ideas Beyond Akeso?

If Akeso is on your radar, it often helps to set it beside a wider watchlist. The Simply Wall St Screener can surface other opportunities that match your preferred mix of quality, risk, and income so you are not relying on a single story.

• If you want potential upside with strict quality filters, scan a curated group of 618 high quality undiscovered gems that pair solid fundamentals with lower market attention.
• If capital resilience matters most to you, focus on defence first by reviewing a 224 resilient stocks with low risk scores that scores well on balance sheet strength and earnings stability.
• If dividends are central to your plan, concentrate on income by reviewing a set of 221 dividend fortresses that combine robust yields with underlying business strength.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com